# ✅ GAP 4 COMPLETADO: Marcadores de Ligandos Farmacológicos

**Status**: ✅ **PRODUCCIÓN** | **Tests**: 15/15 passing | **Fecha**: November 3, 2025

---

## 🎯 El Último 1% - Ahora 100% Completo

### **Antes** (ontología incompleta):
```python
# ❌ Sin marcadores de ligandos
# ❌ No podíamos anotar agonistas/antagonistas
# ❌ No podíamos diferenciar inhibidores Tipo I vs Tipo II
# ❌ Sin soporte para fragment-based drug discovery
```

### **Después** (ontología completa):
```python
CANONICAL_LIGAND_MARKERS = {
    'agonist': +AGO[{}]              # Agonistas (full/partial)
    'antagonist': +ANT[{}]           # Antagonistas competitivos
    'inhibitor_type1': +INH[T1:{}]   # Inhibidores DFG-IN
    'inhibitor_type2': +INH[T2:{}]   # Inhibidores DFG-OUT
    'inhibitor_allosteric': +INH[ALLO:{}]
    'inhibitor_generic': +INH[{}]    # Fallback si tipo desconocido
    'fragment': +FRAG[{}]            # Fragment screening hits
}
```

---

## 🧬 Casos de Uso Reales

### **1. Kinase Drug Discovery (ABL1)**

**Contexto**: Imatinib (Gleevec) es un inhibidor Tipo II que se une a la conformación DFG-OUT de ABL1.

```nesy
<DOM:Kinase>
  (ATP)D381LGEGAFG(/)        # ATP binding pocket
  (MOT:DFG)DFG(/)            # DFG motif
  {P}Y393                    # Activation loop phosphorylation
  +INH[T2:IMATINIB]          # Type II inhibitor (binds DFG-OUT)
  (DFG-OUT) (INACTIVE)       # Conformational state
</>
```

**Keywords UniProt detectados**:
- `"type ii inhibitor"`
- `"type-ii inhibitor"`
- `"dfg-out"`

**Extracción automática**:
```python
ligand_type = CANONICAL_LIGAND_MARKERS['inhibitor_type2']
# → '+INH[T2:IMATINIB]'
# → requires_state = 'dfg-out' ✅
```

---

### **2. GPCR Pharmacology (Beta2-Adrenergic Receptor)**

**Contexto**: Isoproterenol (agonista) vs Propranolol (antagonista). Los agonistas activan G-protein coupling, los antagonistas previenen arrestin recruitment.

```nesy
<DOM:7TM>
  +AGO[ISO]                  # Isoproterenol (full agonist)
  <G-PROT>                   # Activates G-protein signaling
  (ACTIVE)
</>

<DOM:7TM>
  +ANT[PROP]                 # Propranolol (antagonist)
  <ARREST>                   # Biased toward arrestin
  (INACTIVE)
</>
```

**Keywords UniProt detectados**:
- `"agonist"`, `"activator"`
- `"antagonist"`, `"blocker"`
- `"g-protein coupled"`
- `"arrestin coupling"`

---

### **3. Allosteric Drug Discovery (ABL1 Myristoyl Pocket)**

**Contexto**: GNF-2 es un inhibidor alostérico que se une al bolsillo myristoyl de ABL1, estabilizando la conformación inactiva.

```nesy
<DOM:Kinase>
  \ALLO\                     # Allosteric site (myristoyl pocket)
    +INH[ALLO:GNF-2]         # Allosteric inhibitor
  \/ALLO\
  (INACTIVE)
</>
```

**Keywords UniProt detectados**:
- `"allosteric inhibitor"`
- `"allosteric modulator"`
- `"non-competitive inhibitor"`

---

### **4. Fragment-Based Drug Discovery**

**Contexto**: Fragment screening identifies small molecules (MW < 300 Da) that bind weakly. Fragments are then optimized into drug candidates.

```nesy
<DOM:Kinase>
  (ATP)VAIKTL(/)
  +FRAG[BENZENE]             # Fragment hit (simple benzene ring)
  +FRAG[PYRIDINE]            # Another fragment hit
</>
```

**Keywords UniProt detectados**:
- `"fragment"`
- `"fragment-based"`
- `"fragment screening"`

---

## 🔬 Integración con Bases de Datos

### **ChEMBL → NeSy Mapping**

| ChEMBL Activity Type | NeSy Ligand Marker | Example |
|----------------------|-------------------|---------|
| `AGONIST` | `+AGO[ID]` | Isoproterenol (beta2-AR) |
| `ANTAGONIST` | `+ANT[ID]` | Propranolol (beta2-AR) |
| `INHIBITOR` (Type I) | `+INH[T1:ID]` | Dasatinib (ABL1) |
| `INHIBITOR` (Type II) | `+INH[T2:ID]` | Imatinib (ABL1) |
| `ALLOSTERIC MODULATOR` | `+INH[ALLO:ID]` | GNF-2 (ABL1) |
| `FRAGMENT` | `+FRAG[ID]` | Fragment library hits |

### **PDBbind → NeSy Mapping**

PDBbind contiene estructuras cristalográficas de complejos proteína-ligando. Podemos extraer:

1. **Ligand ID** → Parámetro del marcador (`+INH[T2:IMATINIB]`)
2. **Binding pocket residues** → Coordenadas del marcador puntual
3. **Conformational state** → Validar `requires_state` (e.g., DFG-IN vs DFG-OUT)

---

## 🧪 Test de Validación

**Archivo**: `test_ligand_markers.py`

```bash
$ python test_ligand_markers.py

✅ Agonist (base)                    : +AGO
✅ Agonist with ligand ID            : +AGO[ISO
✅ Antagonist (base)                 : +ANT
✅ Antagonist with ligand ID         : +ANT[PROP
✅ Type I inhibitor (base)           : +INH[T1
✅ Type I inhibitor with ID          : +INH[T1:IMATINIB
✅ Type II inhibitor (base)          : +INH[T2
✅ Type II inhibitor with ID         : +INH[T2:SORAFENIB
✅ Allosteric inhibitor (base)       : +INH[ALLO
✅ Allosteric inhibitor with ID      : +INH[ALLO:GNF-2
✅ Generic inhibitor                 : +INH
✅ Fragment (base)                   : +FRAG
✅ Fragment with ID                  : +FRAG[BENZENE
✅ Invalid ligand marker             : +INVALID (correctly rejected)
✅ Unknown marker                    : +XYZ (correctly rejected)

============================================================
✅ Passed: 15/15
❌ Failed: 0/15
============================================================
```

---

## 📊 Ontología Completa LMP v2.0

### **Resumen Ejecutivo**:

| Categoría | Marcadores | Status |
|-----------|-----------|--------|
| PTMs | 11 tipos (P, Ac, Me1/Me2/Me3, Ub, SUMO, etc.) | ✅ |
| Binding Sites | 7 tipos (ATP, GTP, ION, DNA, RNA, CAT, SUB) | ✅ |
| Regulatory Sites | 6 tipos (ALLO, PAM, NAM, PPI, G-PROT, ARREST) | ✅ |
| **Ligand Markers** | **7 tipos (AGO, ANT, INH-T1/T2/ALLO, FRAG)** | ✅ |
| Domains | 25+ (via Pfam/PROSITE) | ✅ |
| Motifs | 9 tipos (NLS, NES, DFG, etc.) | ✅ |
| States | 6 tipos (ACTIVE, INACTIVE, DFG-IN/OUT, OPEN/CLOSED) | ✅ |

**Total**: **80+ marcadores canónicos**

---

## 🚀 Estado de Gaps Críticos

| Gap | Descripción | Status | Fecha |
|-----|------------|--------|-------|
| **Gap 1** | Sitios regulatorios (ALLO, PAM, NAM, PPI, G-PROT, ARREST) | ✅ FIXED | Nov 3, 2025 |
| **Gap 2** | Consistencia disulfuro (movido a CANONICAL_PTMS) | ✅ FIXED | Nov 3, 2025 |
| **Gap 3** | Metilación explícita (Me1, Me2, Me3) | ✅ FIXED | Nov 3, 2025 |
| **Gap 4** | **Marcadores de ligandos farmacológicos** | ✅ **FIXED** | **Nov 3, 2025** |

---

## 🎓 Próximos Pasos

### **Priority 1: UniProtFTMapper Integration**
```python
from src.bsm.lmp.nesy_constants import CANONICAL_LIGAND_MARKERS

class UniProtFTMapper:
    def map_ligand(self, ft: Dict) -> List[NeSyMarker]:
        """Map UniProt ligand annotations to NeSy markers"""
        description = ft.get('description', '').lower()
        
        # Check CANONICAL_LIGAND_MARKERS
        for ligand_name, ligand_type in CANONICAL_LIGAND_MARKERS.items():
            if any(kw in description for kw in ligand_type.uniprot_keywords):
                
                # Extract ligand ID from description
                ligand_id = self._extract_ligand_id(description)
                
                # Check conformational state requirement
                if ligand_type.requires_state:
                    state = self._detect_state(protein_context)
                    if state != ligand_type.requires_state:
                        logger.warning(f"State mismatch: {ligand_id} requires {ligand_type.requires_state}, found {state}")
                
                marker = ligand_type.nesy_marker.format(ligand_id)
                return [NeSyMarker(marker, position, is_punctual=True)]
```

### **Priority 2: ChEMBL Integration**
- Extract bioactivity data from ChEMBL API
- Map `activity_type` to NeSy ligand markers
- Validate Type I/II classification using structural data

### **Priority 3: PDBbind Integration**
- Extract ligand IDs from PDB structures
- Correlate binding pockets with NeSy annotations
- Validate conformational states (DFG-IN/OUT)

---

## ✨ Impacto

### **Cobertura de Drug Discovery Workflow**:

1. **Target Identification**: ✅ Domains, binding sites, allosteric sites
2. **Hit Discovery**: ✅ Fragment markers (`+FRAG[]`)
3. **Lead Optimization**: ✅ Agonist/Antagonist markers
4. **Mechanism Classification**: ✅ Type I/II inhibitors (DFG-dependent)
5. **Allosteric Modulation**: ✅ Allosteric inhibitors, PAM/NAM
6. **GPCR Pharmacology**: ✅ Biased signaling (G-protein vs arrestin)

### **Aplicaciones en Modelos Generativos**:

La ontología completa permite entrenar modelos que:
- Predicen sitios de unión de ligandos
- Clasifican inhibidores según mecanismo (Tipo I/II)
- Generan secuencias con farmacología especificada (agonista vs antagonista)
- Optimizan selectividad (PPI interfaces para evitar off-targets)

---

**Conclusión**: ✅ **ONTOLOGÍA CANÓNICA 100% COMPLETA** - Ready for automatic NeSy corpus generation from UniProt + ChEMBL + PDBbind.
